IL111533A - Quinoxalinedione derivatives and pharmaceutical compositions containing the same - Google Patents
Quinoxalinedione derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL111533A IL111533A IL11153394A IL11153394A IL111533A IL 111533 A IL111533 A IL 111533A IL 11153394 A IL11153394 A IL 11153394A IL 11153394 A IL11153394 A IL 11153394A IL 111533 A IL111533 A IL 111533A
- Authority
- IL
- Israel
- Prior art keywords
- dione
- dihydroquinoxaline
- nitro
- mmol
- nmr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14826893A | 1993-11-05 | 1993-11-05 | |
US08/148,259 US5514680A (en) | 1992-06-22 | 1993-11-05 | Glycine receptor antagonists and the use thereof |
US20887894A | 1994-03-11 | 1994-03-11 | |
US08/289,603 US5631373A (en) | 1993-11-05 | 1994-08-11 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
Publications (2)
Publication Number | Publication Date |
---|---|
IL111533A0 IL111533A0 (en) | 1995-01-24 |
IL111533A true IL111533A (en) | 2001-06-14 |
Family
ID=27495799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11153394A IL111533A (en) | 1993-11-05 | 1994-11-06 | Quinoxalinedione derivatives and pharmaceutical compositions containing the same |
Country Status (10)
Country | Link |
---|---|
US (4) | US5631373A (ja) |
EP (1) | EP0732942A4 (ja) |
JP (1) | JP4164547B2 (ja) |
AU (1) | AU699353B2 (ja) |
CA (1) | CA2175795A1 (ja) |
FI (1) | FI961858A (ja) |
IL (1) | IL111533A (ja) |
NO (1) | NO309981B1 (ja) |
NZ (1) | NZ276892A (ja) |
WO (1) | WO1995012417A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631373A (en) * | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
EP0705834A1 (de) * | 1994-07-27 | 1996-04-10 | Ciba-Geigy Ag | Azaaliphatisch Überbrückte Chinoxalin-2,3-dione |
EP0705835A1 (de) * | 1994-09-01 | 1996-04-10 | Ciba-Geigy Ag | Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione |
US5654303A (en) * | 1995-06-07 | 1997-08-05 | Warner-Lambert Company | Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
US5566694A (en) * | 1995-06-07 | 1996-10-22 | Allegheny Plastics, Inc. | Continuous pickling tank with expandable seals |
US5614508A (en) * | 1995-06-07 | 1997-03-25 | Warner-Lambert Company | Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists |
MY132385A (en) * | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
GB9604400D0 (en) * | 1996-03-01 | 1996-05-01 | Pfizer Ltd | Compounds useful in therapy |
AUPN842196A0 (en) * | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
AU3133697A (en) | 1996-06-05 | 1998-01-05 | Warner-Lambert Company | Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
US6063774A (en) * | 1996-12-16 | 2000-05-16 | Warner-Lambert Company | Tricyclic quinoxaline derivatives as neuroprotective agents |
TW403740B (en) | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
US6329375B1 (en) * | 1997-08-05 | 2001-12-11 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
AU4013900A (en) | 1999-03-19 | 2000-10-09 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
BR0315008A (pt) | 2002-10-04 | 2005-08-09 | Prana Biotechnology Ltd | Compostos neurologicamente ativos |
EP1562555A2 (en) * | 2002-10-24 | 2005-08-17 | Enos Pharmaceuticals, Inc. | Sustained release l-arginine formulations and methods of manufacture and use |
US20080145424A1 (en) * | 2002-10-24 | 2008-06-19 | Enos Phramaceuticals, Inc. | Sustained release L-arginine formulations and methods of manufacture and use |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
GB2398636A (en) | 2003-02-21 | 2004-08-25 | Ipsen Ltd | Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample |
CA2540202A1 (en) * | 2003-09-29 | 2005-04-21 | Enos Pharmaceuticals, Inc. | Sustained release l-arginine formulations and methods of manufacture and use |
BRPI0710737A2 (pt) | 2006-04-14 | 2011-05-10 | Prana Biotechnology Ltd | uso de compostos pb-10 33 éteis para o tratamento de degeneraÇço macular relacionada À idade (amd), assim como referidos compostos |
EP1902733A1 (en) * | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
US7645558B2 (en) * | 2007-06-13 | 2010-01-12 | Xerox Corporation | Inkless reimageable printing paper and method |
US20100316678A1 (en) * | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
EP2254420A4 (en) | 2008-02-20 | 2012-02-15 | Targia Pharmaceuticals | CNS PHARMACEUTICALS AND METHOD FOR THEIR USE |
MY155695A (en) | 2008-06-16 | 2015-11-13 | Merck Patent Gmbh | Quinoxalinedione derivatives |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3962440A (en) * | 1973-12-26 | 1976-06-08 | Eli Lilly And Company | Quinoxaline compounds as hypnotic agents |
US3992378A (en) * | 1973-12-26 | 1976-11-16 | Eli Lilly And Company | Fluoralkyl quinoxadinediones |
DE2446543A1 (de) * | 1974-09-28 | 1976-04-15 | Hoechst Ag | Wasserunloesliche monoazomethinfarbstoffe, verfahren zu ihrer herstellung und ihre verwendung |
DE2451049A1 (de) * | 1974-10-26 | 1976-04-29 | Hoechst Ag | Perinon-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbmittel |
DE2847285A1 (de) * | 1978-10-31 | 1980-05-14 | Hoechst Ag | Monoazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
US4659713A (en) * | 1984-10-01 | 1987-04-21 | International Minerals & Chemical Corp. | Quinoxalinedione compounds useful for controlling coccidiosis |
US4803270A (en) * | 1986-03-10 | 1989-02-07 | Sumitomo Chemical Company, Limited | Process of producing fluoroaniline derivatives |
US4812458A (en) * | 1986-09-16 | 1989-03-14 | A/S Ferrosan | 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics |
DK146787A (da) * | 1987-03-23 | 1988-09-24 | Ferrosan | Heterocykliske forbindelser, deres fremstilling og anvendelse |
NO179551C (no) * | 1987-11-10 | 1996-10-30 | Novo Nordisk As | Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser |
DK160941C (da) * | 1988-06-28 | 1991-10-21 | Novo Nordisk As | Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar |
DK715888D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
US5308845A (en) * | 1988-12-22 | 1994-05-03 | Novo Nordisk A/S | Quinoxaline compounds and their preparation and use |
DK716188D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
US5182258A (en) | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
US4975430A (en) * | 1989-06-16 | 1990-12-04 | The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University | CNQX and its analogs as therapeutics for degenerative neural diseases |
DK69790D0 (da) * | 1990-03-16 | 1990-03-16 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling af anvendelse |
US5268378A (en) * | 1990-05-31 | 1993-12-07 | Merck Sharp & Dohme, Limited | Dioxo-tetrahydroquinoline derivatives |
DE69132340T2 (de) * | 1990-11-06 | 2001-02-08 | Yamanouchi Pharmaceutical Co., Ltd. | Kondensiertes pyrazinderivat |
WO1992011245A1 (en) * | 1990-12-20 | 1992-07-09 | Warner-Lambert Company | 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity |
PT99864B (pt) * | 1990-12-21 | 1999-06-30 | Schering Ag | Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato |
DK73091D0 (da) * | 1991-04-22 | 1991-04-22 | Novo Nordisk As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
US5196421A (en) * | 1991-06-05 | 1993-03-23 | Eli Lilly And Company | Excitatory amino acid receptor antagonists in methods for the use thereof |
JPH05117276A (ja) * | 1991-10-23 | 1993-05-14 | Sumitomo Pharmaceut Co Ltd | 新規な3環性キノキサリンジオン誘導体 |
KR100304017B1 (ko) * | 1992-06-22 | 2001-11-22 | 추후제출 | 글리신수용체길항물질및이의용도 |
DE4220616C2 (de) * | 1992-06-24 | 1994-12-22 | Byk Gulden Lomberg Chem Fab | Dexniguldipin zur intravenösen Verabreichung |
US5352683A (en) * | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
US5631373A (en) * | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
US6172065B1 (en) * | 1997-03-04 | 2001-01-09 | Warner-Lambert Company | Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
US6166019A (en) * | 1998-07-16 | 2000-12-26 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
-
1994
- 1994-08-11 US US08/289,603 patent/US5631373A/en not_active Expired - Lifetime
- 1994-11-06 IL IL11153394A patent/IL111533A/en not_active IP Right Cessation
- 1994-11-07 CA CA002175795A patent/CA2175795A1/en not_active Abandoned
- 1994-11-07 NZ NZ276892A patent/NZ276892A/xx not_active IP Right Cessation
- 1994-11-07 AU AU11723/95A patent/AU699353B2/en not_active Ceased
- 1994-11-07 WO PCT/US1994/012775 patent/WO1995012417A1/en active Application Filing
- 1994-11-07 JP JP51345295A patent/JP4164547B2/ja not_active Expired - Fee Related
- 1994-11-07 EP EP95902458A patent/EP0732942A4/en not_active Withdrawn
-
1996
- 1996-05-02 FI FI961858A patent/FI961858A/fi not_active Application Discontinuation
- 1996-05-02 NO NO961770A patent/NO309981B1/no not_active IP Right Cessation
-
1997
- 1997-01-31 US US08/792,872 patent/US5977107A/en not_active Expired - Fee Related
-
1999
- 1999-08-18 US US09/376,536 patent/US6147075A/en not_active Expired - Fee Related
-
2000
- 2000-09-13 US US09/661,475 patent/US6251903B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NZ276892A (en) | 2000-01-28 |
AU1172395A (en) | 1995-05-23 |
NO309981B1 (no) | 2001-04-30 |
AU699353B2 (en) | 1998-12-03 |
CA2175795A1 (en) | 1995-05-11 |
JPH09504794A (ja) | 1997-05-13 |
FI961858A0 (fi) | 1996-05-02 |
WO1995012417A1 (en) | 1995-05-11 |
EP0732942A1 (en) | 1996-09-25 |
EP0732942A4 (en) | 2000-03-22 |
NO961770L (no) | 1996-07-05 |
NO961770D0 (no) | 1996-05-02 |
US6147075A (en) | 2000-11-14 |
FI961858A (fi) | 1996-07-04 |
US6251903B1 (en) | 2001-06-26 |
US5977107A (en) | 1999-11-02 |
IL111533A0 (en) | 1995-01-24 |
JP4164547B2 (ja) | 2008-10-15 |
US5631373A (en) | 1997-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6147075A (en) | Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | |
US5620979A (en) | Glycine receptor antagonists and the use thereof | |
US5801183A (en) | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists | |
US5620978A (en) | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | |
US5597922A (en) | Glycine receptor antagonist pharmacophore | |
EP0706396B1 (en) | 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and use | |
US5622965A (en) | 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists | |
KR100372120B1 (ko) | 알킬,아지도,알콕시및플루오로치환되고융합된퀴녹살린디온및이것을글린신수용체길항물질로사용하는방법 | |
WO1994007500A1 (en) | 2,5-dihydro-2,5-dioxo-1h-azepines and 2,5-dihydro-2-oxo-1h-azepines and the use thereof as excitatory amino acid and glycine receptor antagonists | |
WO1996040141A1 (en) | 4,5-bridged quinoxalinediones and quinolones and the use thereof as excitatory amino acid receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |